WO2002022809A3 - PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST - Google Patents

PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST Download PDF

Info

Publication number
WO2002022809A3
WO2002022809A3 PCT/US2001/029229 US0129229W WO0222809A3 WO 2002022809 A3 WO2002022809 A3 WO 2002022809A3 US 0129229 W US0129229 W US 0129229W WO 0222809 A3 WO0222809 A3 WO 0222809A3
Authority
WO
WIPO (PCT)
Prior art keywords
murine
tlr8
tlr7
tlr9
well
Prior art date
Application number
PCT/US2001/029229
Other languages
French (fr)
Other versions
WO2002022809A2 (en
WO2002022809A9 (en
Inventor
Stefan Bauer
Grayson Lipford
Hermann Wagner
Original Assignee
Coley Pharm Gmbh
Stefan Bauer
Grayson Lipford
Hermann Wagner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharm Gmbh, Stefan Bauer, Grayson Lipford, Hermann Wagner filed Critical Coley Pharm Gmbh
Priority to AT01971181T priority Critical patent/ATE510850T1/en
Priority to EP01971181A priority patent/EP1366077B1/en
Priority to JP2002527251A priority patent/JP2005500806A/en
Priority to CA002419894A priority patent/CA2419894A1/en
Priority to AU2001291096A priority patent/AU2001291096A1/en
Priority to DK01971181.1T priority patent/DK1366077T3/en
Publication of WO2002022809A2 publication Critical patent/WO2002022809A2/en
Publication of WO2002022809A9 publication Critical patent/WO2002022809A9/en
Publication of WO2002022809A3 publication Critical patent/WO2002022809A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8. Methods are included for screening for ligands of TLR7 and TLR8, as well as for inhibitors and agonists and antagonists of signaling mediated by TLR7 and TLR8.
PCT/US2001/029229 2000-09-15 2001-09-17 PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST WO2002022809A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT01971181T ATE510850T1 (en) 2000-09-15 2001-09-17 METHOD FOR HIGH-THROUGHPUT SCREENING OF CPG-BASED IMMUNAGONISTS AND ANTAGONISTS
EP01971181A EP1366077B1 (en) 2000-09-15 2001-09-17 PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
JP2002527251A JP2005500806A (en) 2000-09-15 2001-09-17 Process for high-throughput screening of immune agonist / immunoantagonists based on CpG
CA002419894A CA2419894A1 (en) 2000-09-15 2001-09-17 Process for high throughput screening of cpg-based immuno-agonist/antagonist
AU2001291096A AU2001291096A1 (en) 2000-09-15 2001-09-17 Process for high throughput screening of CpG-based immuno-agonist/antagonist
DK01971181.1T DK1366077T3 (en) 2000-09-15 2001-09-17 Method for screening in large quantities of CpG-based immunoagonists / antagonists

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US23303500P 2000-09-15 2000-09-15
US60/233,035 2000-09-15
US26365701P 2001-01-23 2001-01-23
US60/263,657 2001-01-23
US29172601P 2001-05-17 2001-05-17
US60/291,726 2001-05-17
US30021001P 2001-06-22 2001-06-22
US60/300,210 2001-06-22

Publications (3)

Publication Number Publication Date
WO2002022809A2 WO2002022809A2 (en) 2002-03-21
WO2002022809A9 WO2002022809A9 (en) 2003-03-20
WO2002022809A3 true WO2002022809A3 (en) 2003-10-02

Family

ID=27499675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/029229 WO2002022809A2 (en) 2000-09-15 2001-09-17 PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST

Country Status (8)

Country Link
US (2) US6943240B2 (en)
EP (1) EP1366077B1 (en)
JP (1) JP2005500806A (en)
AT (1) ATE510850T1 (en)
AU (1) AU2001291096A1 (en)
CA (1) CA2419894A1 (en)
DK (1) DK1366077T3 (en)
WO (1) WO2002022809A2 (en)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ZA989147B (en) * 1997-10-17 2000-04-07 Genentech Inc Human toll homologues.
AU760549B2 (en) * 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
IL139646A0 (en) * 1998-05-14 2002-02-10 Coley Pharm Group Inc Methods for regulating hematopoiesis using cpg-oligonucleotides
SI1077722T1 (en) * 1998-05-22 2007-02-28 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
CA2362204C (en) * 1999-02-17 2011-11-08 John Cooper Cox Immunogenic complexes and methods relating thereto
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CN1454091A (en) * 1999-09-25 2003-11-05 衣阿华大学研究基金会 Immunostimulatory nucleic acids
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
SI1296714T1 (en) * 2000-06-22 2010-01-29 S For Entpr University Of Iowa Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
JP2002034565A (en) * 2000-07-19 2002-02-05 Japan Science & Technology Corp Receptor protein specifically recognizing bacterial dna
JP2005500806A (en) * 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー Process for high-throughput screening of immune agonist / immunoantagonists based on CpG
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
ES2314099T3 (en) 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh IMMUNO STIMULANT OLIGONUCLEOTIDES WITH REASONS COMBINED WITH IMPROVED ACTIVITY.
KR20050034583A (en) * 2001-10-05 2005-04-14 콜리 파마슈티칼 게엠베하 Toll-like receptor 3 signaling agonists and antagonists
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found Methods and products for enhancing immune responses using imidazoquinoline compounds
EP1459727B1 (en) * 2001-11-22 2010-06-09 Japan Science and Technology Agency Nonhuman model animal unresponsive to immunopotentiating synthetic compound
US20030118569A1 (en) * 2001-12-18 2003-06-26 Bankert Richard B. Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
ES2734652T3 (en) 2002-04-04 2019-12-11 Zoetis Belgium S A Immunostimulatory oligonucleotides containing G and U
WO2003103586A2 (en) * 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
SI2241325T1 (en) * 2002-10-29 2012-05-31 Coley Pharm Group Inc Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004070344A2 (en) * 2003-02-04 2004-08-19 Bayer Healthcare Ag Method of screening for agents which modulate the activity of tlr9
JP2006517974A (en) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Methods and compositions for IRM compounds and Toll-like receptor 8
EP1599726A4 (en) * 2003-02-27 2009-07-22 3M Innovative Properties Co Selective modulation of tlr-mediated biological activity
EP1613956A2 (en) * 2003-03-25 2006-01-11 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
EP1608403A2 (en) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP1631687A2 (en) * 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Methods and products for identification and assessment of tlr ligands
EP1635846A4 (en) * 2003-06-20 2009-01-28 Coley Pharm Gmbh Small molecule toll-like receptor (tlr) antagonists
TW200524927A (en) 2003-08-12 2005-08-01 3M Innovative Properties Co Hydroxylamine substituted imidazo-containing compounds
WO2005020999A1 (en) 2003-08-27 2005-03-10 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (en) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Method for treating CD5 + B cell lymphoma
US7615539B2 (en) * 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
KR101154101B1 (en) 2003-10-03 2012-06-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US8188254B2 (en) 2003-10-30 2012-05-29 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
US7897767B2 (en) 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
CN1906192A (en) 2003-11-14 2007-01-31 3M创新有限公司 Hydroxylamine substituted imidazo ring compounds
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
WO2005059517A2 (en) * 2003-12-16 2005-06-30 University Of Massachusetts Toll-like receptor assays
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
EP2415481A3 (en) * 2004-02-19 2012-04-18 Coley Pharmaceutical Group, Inc. Immunostimulatory viral RNA oligonucleotides
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
US20050244410A1 (en) * 2004-04-29 2005-11-03 Ashlyn Bassiri Toll-like receptor 9 effector agents and uses thereof
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
EP1781325A2 (en) 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
GB0424497D0 (en) * 2004-11-05 2004-12-08 Univ Sheffield Anti-inflammatory agent
CA2589487C (en) 2004-11-29 2014-07-29 Klinikum Der Universitat Regensburg Means and methods for detecting methylated dna
CN102220412B (en) 2004-11-29 2016-04-13 塞昆纳姆股份有限公司 For detecting test kit and the method for methylate DNA
CA2594674C (en) 2004-12-30 2016-05-17 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
JP5543068B2 (en) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー Chiral fused [1,2] imidazo [4,5-c] cyclic compound
CN100485034C (en) * 2005-01-28 2009-05-06 权滢周 Oligonucleotides extracted from mycobacteria for stimulating immune function, treating immune-related diseases, allergic dermatitis and/or protecting normal immune cells
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
DE102005005642A1 (en) * 2005-02-06 2006-08-10 Phenion Gmbh & Co. Kg Cosmetic or pharmaceutical preparations containing nucleic acids comprising sequences suitable for the formation of stem-loop secondary structures
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US7700728B2 (en) * 2005-03-24 2010-04-20 Schering Corporation Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors
US7498409B2 (en) * 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
JP2008148556A (en) * 2005-03-31 2008-07-03 Univ Of Tokyo METHOD FOR SCREENING AUXILIARY AGENT CAPABLE OF PROMOTING EXPRESSION INDUCTION OF INTERFERON-alpha AND/OR -beta (IFN-alpha/beta)
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2609788A1 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
CA2612162C (en) 2005-07-01 2016-05-17 Index Pharmaceuticals Ab Use of oligonucleotides in steroid refractory or steroid dependent inflammatory conditions
EP2179737B1 (en) 2005-07-01 2013-08-14 Index Pharmaceuticals AB Modulating responsiveness to steroids
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
AU2006294528A1 (en) * 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of TLR-mediated immune responses using adaptor oligonucleotides
AU2006306805A1 (en) * 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US20090082295A1 (en) * 2005-11-11 2009-03-26 Pfizer Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
EP1957647B1 (en) 2005-11-25 2015-03-04 Zoetis Belgium S.A. Immunostimulatory oligoribonucleotides
JP2009536022A (en) * 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド Novel gene disruption and related compositions and methods
US7915399B2 (en) * 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US20080171716A1 (en) * 2006-08-16 2008-07-17 Protiva Biotherapeutics, Inc. Nucleic acid modulation of toll-like receptor-mediated immune stimulation
CN101517082B (en) 2006-09-27 2014-01-22 科勒制药有限责任公司 Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2009013157A1 (en) * 2007-07-23 2009-01-29 Dsm Ip Assets B.V. Butanol production in a eukaryotic cell
US20100040576A1 (en) * 2007-12-18 2010-02-18 The Texas A&M University System Modified Oligonucleotides For The Treatment Of Hepatitis C Infection
JP2011529501A (en) * 2008-07-28 2011-12-08 イデラ ファーマシューティカルズ インコーポレイテッド Regulation of Toll-like receptor 9 expression by antisense oligonucleotides
US8865321B2 (en) * 2008-11-11 2014-10-21 Merck Patent Gmbh Organic electroluminescent devices
ES2616051T3 (en) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Method for the synthesis of modified nucleic acids in the phosphorus atom
DK2396347T3 (en) 2009-02-11 2017-07-24 Albumedix As ALBUMIN VARIANTS AND CONJUGATES
PL2411521T3 (en) 2009-03-25 2015-08-31 Univ Texas Compositions for stimulation of mammalian innate immune resistance to pathogens
FR2945538B1 (en) * 2009-05-12 2014-12-26 Sanofi Aventis HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLARY FORM OF THE BETA-AMYLOID PEPTIDE.
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
EP2451974A2 (en) * 2009-07-08 2012-05-16 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
BR112012009450A2 (en) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As albumin variants
CN102939304B (en) 2010-04-09 2017-04-19 阿尔布麦狄克斯公司 albumin derivatives and variants
US9186371B2 (en) 2010-09-17 2015-11-17 Japan Science And Technology Agency Inhibitor of HMGB protein-mediated immune response activation, and screening method
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
WO2013119193A2 (en) * 2010-10-21 2013-08-15 Tufts University Extracellular mitochondria-based screening and treatment
US9063123B2 (en) 2011-03-29 2015-06-23 Dynavax Technologies Corporation Transgenic mice expressing human toll-like receptor 8
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
DK2812434T3 (en) * 2012-02-09 2018-07-16 Bavarian Nordic As AGONISTS AND ANTAGONISTS OF TOLL-LIKE RECEPTOR-13 (TLR-13)
KR20140136934A (en) 2012-03-16 2014-12-01 노보자임스 바이오파마 디케이 에이/에스 Albumin variants
CN107011400B (en) 2012-07-13 2021-05-25 波涛生命科学有限公司 Asymmetric auxiliary group
KR20150082422A (en) 2012-11-08 2015-07-15 노보자임스 바이오파마 디케이 에이/에스 Albumin variants
US10259863B2 (en) 2013-01-11 2019-04-16 The California Institute For Biomedical Research Bovine fusion antibodies
CA2918370A1 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10149905B2 (en) * 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10144933B2 (en) * 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
KR102423317B1 (en) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 Chiral design
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
CA2989966A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
US11319343B2 (en) 2017-06-30 2022-05-03 Royal Melbourne Institute Of Technology Method of treatment
WO2020041590A1 (en) * 2018-08-23 2020-02-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tlr9 ligand trap
US11393560B2 (en) 2018-11-13 2022-07-19 Recursion Pharmaceuticals, Inc. Systems and methods for high throughput compound library creation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055386A1 (en) * 2000-01-25 2001-08-02 Glaxosmithkline Toll-like receptor

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567604A (en) 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
ATE301201T1 (en) 1993-06-07 2005-08-15 Vical Inc PLASMIDS USABLE FOR GENE THERAPY
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
DE19502912A1 (en) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilized Oligonucleotides
HUP9801629A3 (en) 1995-02-09 2000-10-30 Icn Pharmaceuticals Inc Costa Methods and compositions for regulation of cd28 expression
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
PL334197A1 (en) 1996-12-27 2000-02-14 Icn Pharmaceuticals Oligonucleotidic aptamers of high g content and methods of modulating immunilogical response
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
JP2002514083A (en) 1997-05-07 2002-05-14 シェーリング コーポレイション Human Toll-like receptor proteins, related reagents and methods
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
EP1009440B1 (en) 1997-07-03 2008-09-17 MacFarlane, Donald E. Method for inhibiting immunostimulatory dna associated responses
AU1070399A (en) 1997-10-17 1999-05-10 Genentech Inc. Human toll homologues
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
IL139646A0 (en) 1998-05-14 2002-02-10 Coley Pharm Group Inc Methods for regulating hematopoiesis using cpg-oligonucleotides
SI1077722T1 (en) 1998-05-22 2007-02-28 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
JP2002521489A (en) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Stereoisomers of CpG oligonucleotides and related methods
WO2000014217A2 (en) 1998-09-03 2000-03-16 Coley Pharmaceutical Gmbh G-motif oligonucleotides and uses thereof
ATE405155T1 (en) 1999-01-14 2008-09-15 Japan Science & Tech Agency MODEL MOUSE THAT DOES NOT RESPOND TO BACTERIAL CELL COMPONENTS.
WO2000067023A1 (en) 1999-04-29 2000-11-09 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
CA2412345A1 (en) 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
CN1454091A (en) 1999-09-25 2003-11-05 衣阿华大学研究基金会 Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
WO2001022990A2 (en) 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
WO2001032877A2 (en) 1999-11-02 2001-05-10 Chiron Corporation CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US6339630B1 (en) 2000-05-18 2002-01-15 The United States Of America As Represented By The United States Department Of Energy Sealed drive screw operator
SI1296714T1 (en) 2000-06-22 2010-01-29 S For Entpr University Of Iowa Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US20020165178A1 (en) * 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020091097A1 (en) 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
JP2005500806A (en) 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー Process for high-throughput screening of immune agonist / immunoantagonists based on CpG
WO2002069369A2 (en) 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
AU2002248185A1 (en) * 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
AU2002360243A1 (en) 2001-07-26 2003-05-06 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
ES2314099T3 (en) * 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh IMMUNO STIMULANT OLIGONUCLEOTIDES WITH REASONS COMBINED WITH IMPROVED ACTIVITY.
US20030067902A1 (en) 2001-09-21 2003-04-10 Skeba Kirk W. Method for providing multiple certified radio modules with a baseband
KR20050034583A (en) * 2001-10-05 2005-04-14 콜리 파마슈티칼 게엠베하 Toll-like receptor 3 signaling agonists and antagonists
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003043572A2 (en) 2001-11-16 2003-05-30 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
ES2734652T3 (en) 2002-04-04 2019-12-11 Zoetis Belgium S A Immunostimulatory oligonucleotides containing G and U
WO2003103586A2 (en) 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2003255969A1 (en) 2002-07-17 2004-02-02 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
AU2003278845A1 (en) 2002-09-19 2004-04-08 Coley Pharmaceutical Gmbh Toll-like receptor 9 (tlr9) from various mammalian species
SI2241325T1 (en) 2002-10-29 2012-05-31 Coley Pharm Group Inc Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
EP1608403A2 (en) 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP1631687A2 (en) 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Methods and products for identification and assessment of tlr ligands
EP1635846A4 (en) 2003-06-20 2009-01-28 Coley Pharm Gmbh Small molecule toll-like receptor (tlr) antagonists
US7615539B2 (en) 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
US8188254B2 (en) 2003-10-30 2012-05-29 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
EP2415481A3 (en) 2004-02-19 2012-04-18 Coley Pharmaceutical Group, Inc. Immunostimulatory viral RNA oligonucleotides
US20060019916A1 (en) 2004-04-02 2006-01-26 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing IL-10 responses
CA2574090A1 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055386A1 (en) * 2000-01-25 2001-08-02 Glaxosmithkline Toll-like receptor

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BAUER STEFAN ET AL: "Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 16, 31 July 2001 (2001-07-31), July 31, 2001, pages 9237 - 9242, XP002221247, ISSN: 0027-8424 *
CHUANG TSUNG-HSIEN ET AL: "Toll-like receptor 9 mediates CpG-DNA signaling.", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 71, no. 3, March 2002 (2002-03-01), March, 2002, pages 538 - 544, XP009001226, ISSN: 0741-5400 *
DATABASE EMBL [online] EBI; 2 August 1999 (1999-08-02), XP002221249, retrieved from EMBL Database accession no. AAY05867 *
DATABASE EMBL [online] EBI; 5 April 2001 (2001-04-05), XP002221250, retrieved from EMBL Database accession no. AF348140 *
DU XIN ET AL: "Three novel mammalian toll-like receptors: Gene structure, expression, and evolution.", EUROPEAN CYTOKINE NETWORK, vol. 11, no. 3, September 2000 (2000-09-01), pages 362 - 371, XP009000972, ISSN: 1148-5493 *
HEMMI HIROAKI ET AL: "A Toll-like receptor recognizes bacterial DNA.", NATURE (LONDON), vol. 408, no. 6813, 2000, pages 740 - 745, XP002221246, ISSN: 0028-0836 *
HOSHINO K ET AL: "Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 APR 1999, vol. 162, no. 7, 1 April 1999 (1999-04-01), pages 3749 - 3752, XP002221244, ISSN: 0022-1767 *
KOPP E B ET AL: "The Toll-receptor family and control of innate immunity", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 11, no. 1, 1 February 1999 (1999-02-01), pages 13 - 18, XP004257650, ISSN: 0952-7915 *
MUZIO MARTA ET AL: "Toll-like receptors.", MICROBES AND INFECTION, vol. 2, no. 3, March 2000 (2000-03-01), pages 251 - 255, XP002221245, ISSN: 1286-4579 *
NATURE, vol. 409, February 2001 (2001-02-01), pages 646, XP002224870 *
TAKEUCHI O ET AL: "TLR6: A novel member of an expanding Toll-like receptor family.", GENE (AMSTERDAM), vol. 231, no. 1-2, 29 April 1999 (1999-04-29), pages 59 - 65, XP004166778, ISSN: 0378-1119 *
XIN DU ET AL: "THREE NOVEL MAMMALIAN TOLL-LIKE RECEPTORS: GENE STRUCTURE, EXPRESSION, AND EVOLUTION", EUROPEAN CYTOKINE NETWORK, JOHN LIBBEY EUROTEXT LTD., MONTROUGE, FR, vol. 11, no. 3, September 2000 (2000-09-01), pages 1 - 14, XP002944897, ISSN: 1148-5493 *

Also Published As

Publication number Publication date
US20030104523A1 (en) 2003-06-05
CA2419894A1 (en) 2002-03-21
US7820379B2 (en) 2010-10-26
WO2002022809A2 (en) 2002-03-21
AU2001291096A1 (en) 2002-03-26
EP1366077B1 (en) 2011-05-25
EP1366077A2 (en) 2003-12-03
ATE510850T1 (en) 2011-06-15
US20050181422A1 (en) 2005-08-18
DK1366077T3 (en) 2011-09-12
JP2005500806A (en) 2005-01-13
WO2002022809A9 (en) 2003-03-20
US6943240B2 (en) 2005-09-13

Similar Documents

Publication Publication Date Title
WO2002022809A3 (en) PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
WO2003086280A3 (en) Immunostimulatory g,u-containing oligoribonucleotides
MXPA03000627A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus.
MXPA03000626A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus.
WO2002008256A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2002259305A8 (en) High affinity ligand for p75 neurotrophin receptor
CA2523467C (en) Treatment of t-cell mediated diseases
EP1408986A4 (en) Proteomimetic compounds and methods
WO2003068798A3 (en) Oligonucleotide analogues and methods of use for modulating gene expression
WO2002008251A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
EP1141286A4 (en) Cytokine receptor chain
EP1668030A4 (en) A method of improving efficacy of biological response-modifying proteins and the exemplary muteins
WO2002060917A3 (en) Method to treat hemophilia
IL138345A0 (en) Novel compositions of epropsartan
PT1137413E (en) NAO-PEPTIDIC ANTAGONISTS OF THE GLP-1 RECEPTOR AND METHODS OF USE
WO2001071007A3 (en) GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF
WO2003106625A3 (en) Hammerhead ribozymes
HUP0102614A2 (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src
IL161296A0 (en) Glycosylphosphatidylinositol containing polypeptides
MXPA05009428A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions.
BR0214613A (en) N-ureide piperidines as ccr-3 receptor antagonists
WO2000075305A3 (en) Candida albicans genes and proteins coded by said genes
WO2001023540A3 (en) P-glycoproteins and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2419894

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 524361

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001291096

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002527251

Country of ref document: JP

COP Corrected version of pamphlet

Free format text: PAGES 1/20-20/20, DRAWINGS, REPLACED BY NEW PAGES 1/20-20/20; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 2001971181

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001971181

Country of ref document: EP